BSc JD - Xintela AB Ex Chairman
| XINT Stock | SEK 0.32 0.01 3.23% |
Insider
BSc JD is Ex Chairman of Xintela AB
| Age | 65 |
| Phone | 46 4 62 75 65 00 |
| Web | https://www.xintela.se |
Xintela AB Management Efficiency
The company has return on total asset (ROA) of (1.1374) % which means that it has lost $1.1374 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.6888) %, meaning that it generated substantial loss on money invested by shareholders. Xintela AB's management efficiency ratios could be used to measure how well Xintela AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MSc | Saniona AB | 63 | |
| Anita BCom | Saniona AB | 55 | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| Pr MD | Oncopeptides AB | N/A | |
| MSc MSc | Oncopeptides AB | 53 | |
| Palle MS | Saniona AB | 65 | |
| Jorgen Drejer | Saniona AB | 68 | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Rami Levin | Saniona AB | 54 | |
| Lars Petersen | ExpreS2ion Biotech Holding | N/A | |
| Bent MSc | ExpreS2ion Biotech Holding | N/A | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Mattis Ranthe | ExpreS2ion Biotech Holding | N/A | |
| Karin Nielsen | Saniona AB | N/A | |
| Max Sogaard | ExpreS2ion Biotech Holding | N/A | |
| MSc MD | Oncopeptides AB | N/A | |
| Janus Larsen | Saniona AB | 51 | |
| Mette Thorn | ExpreS2ion Biotech Holding | N/A | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Sren MSc | Hansa Biopharma AB | 58 | |
Management Performance
| Return On Equity | -4.69 | |||
| Return On Asset | -1.14 |
Xintela AB Leadership Team
Elected by the shareholders, the Xintela AB's board of directors comprises two types of representatives: Xintela AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xintela. The board's role is to monitor Xintela AB's management team and ensure that shareholders' interests are well served. Xintela AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xintela AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BSc JD, Ex Chairman | ||
| Thomas Areschoug, Business Development Manager | ||
| Per Norlen, Chief Officer | ||
| Gunnar Telhammar, CFO Director |
Xintela Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xintela AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.69 | |||
| Return On Asset | -1.14 | |||
| Current Valuation | 122.93 M | |||
| Shares Outstanding | 307.57 M | |||
| Shares Owned By Insiders | 58.76 % | |||
| Price To Earning | (4.40) X | |||
| Price To Book | 11.52 X | |||
| Price To Sales | 5,115 X | |||
| Gross Profit | 2.08 M | |||
| EBITDA | (54.43 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xintela Stock Analysis
When running Xintela AB's price analysis, check to measure Xintela AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xintela AB is operating at the current time. Most of Xintela AB's value examination focuses on studying past and present price action to predict the probability of Xintela AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xintela AB's price. Additionally, you may evaluate how the addition of Xintela AB to your portfolios can decrease your overall portfolio volatility.